Portola Pharmaceuticals to Announce Fourth Quarter and Year-End 2015 Financial Results and Host Conference Call on Friday, Fe...
19 Février 2016 - 2:00PM
Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) announced today that it
will host a webcast and conference call to discuss the Company’s
financial results for the quarter and year ended December 31, 2015,
and provide a general business overview on Friday, February 26,
2016, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time).
Conference Call DetailsTo access
the live conference call, please dial (844) 452-6828 from the U.S.
and Canada or +1(765) 507-2588 internationally, and use the
passcode 48937755. Please dial in 10 minutes prior to the start of
the call. To access the live and subsequently archived webcast of
the conference call, go to the Investor Relations section of the
company’s website at http://investors.portola.com. Please connect
to the website at least 15 minutes prior to the call to allow for
any software download that may be necessary. A replay of the
webcast will be available on the Company’s website for 30 days
following the live event.
About Portola Pharmaceuticals,
Inc. Portola Pharmaceuticals is a biopharmaceutical
company developing product candidates that could significantly
advance the fields of thrombosis and other hematologic diseases.
The Company is advancing its three wholly-owned programs using
novel biomarker and genetic approaches that may increase the
likelihood of clinical, regulatory and commercial success. These
programs include betrixaban, an oral, once-daily Factor Xa
inhibitor being evaluated in the APEX Phase 3 study for prophylaxis
of venous thromboembolism; andexanet alfa, a recombinant protein
designed to reverse the anticoagulant effect in patients treated
with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a
Syk/JAK inhibitor in development to treat hematologic cancers.
Portola's partnered program is focused on developing selective Syk
inhibitors for inflammatory conditions. For more information, visit
www.portola.com and follow the Company on Twitter
@Portola_Pharma.
Investor Contact:
Ana Kapor
Portola Pharmaceuticals
ir@portola.com
Media Contact:
Julie Normart
W2O Group
jnormart@w2ogroup.com
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
Real-Time news about Portola Pharmaceuticals Inc (NASDAQ): 0 recent articles
Plus d'articles sur